- TRADE NAME: Motegrity (Shire)
- INDICATIONS: indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
- CLASS: Serotonin type 4 receptor agonist
- HALF-LIFE: ~1 day
- FDA APPROVAL DATE: 12/14/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: insufficient data to identify any drug-associated risks
Please login to view the rest of this drug profile.
Page last updated 01/06/2024
